Summit Therapeutics Share Discussion Threads

[luminoso] 21/5/2018 13:27

Thanks Hugus. It does not say much for the powers of research of the punters you describe from the nasdaq boards. Basically, those traders are pure momentum traders. If the share price is high, it must be good. If the share price is low, it must be bad ... or something does not add up. It also explains the share price of Sarepta at the moment.

Of course many of these punters will be caught with their pants down, if Sarepta's share price implodes on fundamentals and Summit's share price explodes on likely approval of EZT.

At some point, I expect Sarepta to make a move on EZT, either parts or the whole, as it will become increasingly clear to them that EZT is the most likely candidate around, currently, to make a difference to DMD boys. They have the cash still to achieve that but while the market sleeps with regard to EZT, they still have time before they have to make a move - around 48 week results time maybe ? The big question for me is - will they have any competition to acquire EZT the closer we get to results and, dare I say it, Approval ?

[hugus maximus] 20/5/2018 17:22

Possibly just a couple of months away from DMD P2 48 wk results and we need Summit to start broadcasting a summary of their amazing W-I-P. IMO the idea that a simple repeat of EZD 24 wks data @ 48 wks may be all that's needed to produce a Becker MD type prognosis for DMD boys, must allow the families a real sense of expectation for life changing possibilities. (i.e. Becker MD has a life expectancy of 50's and even 60's ... DMD has a life expectancy of 20's)

Given that the Monaco conference was many weeks ago when Glyn mentioned this, I'm surprised that investment analysts have not even taken this fact on board in updates and it's disappointing to see the share price still hanging around £2.

In the USA, an investor on a message board sums up what I would say is typical NASDAQ punters view of Summit and EZD. They are blinded by what they see as the ridiculous improbability of such a low share price hiding any sort of success:-
"Something doesn't add up"

EDIT: i.e.The general view is : "This can't possibly be a success, as at this stage the share price would not be so low." Of course none of this matters, unless anticipating the opportunity to de-risk a little before 48 wk RNS.

[luminoso] 20/5/2018 17:07

$14 proving a very hard nut to crack.

[chrisatrdg] 18/5/2018 11:05

Not sure football share price still not settled lets see how today goes.

[football] 18/5/2018 01:09

$15 today now $14 has gone?

[solomon] 16/5/2018 22:38

A high volume rise on Nazzy. Does that actually mean anything?
Better than a high volume fall.
Not as good as an astronomical takeoff.

[algernon2] 16/5/2018 11:06

Thanks Guys,suspected it might just be business as usual but wasn't sure.Thanks for the clarification.

[waterloo01] 16/5/2018 08:14

They do shelf filings every year, gives them the option to raise if and when needed.

[football] 16/5/2018 08:11

from link
above


Subject to completion, dated May 15, 2018

$225,000,000

PROSPECTUS




SUMMIT THERAPEUTICS PLC

Debt Securities

Ordinary Shares

American Depositary Shares representing Ordinary Shares

Units

Warrants

We may issue securities from time to time in one or more offerings of up to $225,000,000 in aggregate offering price. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this document. You should read this prospectus and any applicable prospectus supplement carefully before you invest.

We may offer these securities in amounts, at prices and on terms determined at the time of offering. The securities may be sold directly to you, through agents, or through underwriters and dealers. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus supplement.

Our ADSs are listed on The Nasdaq Global Market under the symbol “SMMT.” Our ordinary shares are admitted for trading on AIM, a market operated by the London Stock Exchange plc, or AIM, under the listing code “SUMM.”

[kabo87] 16/5/2018 01:01

hTTps://www.sec.gov/Archives/edgar/data/1599298/000119312518164105/d586412df3.htm

[chrisatrdg] 15/5/2018 13:28

The DMD Clinical trial finder is a brilliant resource if you are tracking research and upcoming trials for #duchenne in the UK. Clinical Trial Finder | DMD Hub

[aim_trader] 15/5/2018 13:06

Summit Therapeutics presenting at Proactive One2One Forum this Thursday evening in London. Details and registration can be found here:

[hugus maximus] 14/5/2018 16:53

Thanks Freedosh ... thought you might suggest that.

EDIT : Then simply a repeat of 24 wk data at 48 wks might possibly be admissible for FDA approval!

[freedosh] 14/5/2018 16:39

I guess it’s a possibility, Hugus.
And a pretty good possibility at that.

[hugus maximus] 14/5/2018 13:03

In addition I came across this:

[hugus maximus] 13/5/2018 16:28

Good afternoon Freedosh.

Hope this finds you happy and health continuing to improve.

Would love to know your thoughts. I wondered if recent reports have changed your opinion of earlier in the year when you suggested that potential FDA approval of EZD was still needing to see some sort of "functional stability or improvement"? I mention this in light of the following:
1. Published 3rd May 2018:


2. Published 19th March 2018:


Many thanks for any informed opinion you might proffer.
On behalf of the great unwashed.
Warmest regards
HM

[hugus maximus] 12/5/2018 10:37

Closing price on NASDAQ $14 = £2.02p AIM.

[football] 11/5/2018 22:01

Yes it's $1 more than $13

:-)

[solomon] 11/5/2018 20:29

$14 does seem to be an emotional border.
edit: yesss .....$14
Does that actually mean anything?

[football] 10/5/2018 20:02

come on $14 ffs

[algernon2] 10/5/2018 13:23

Ok: Thanks HM.

[hugus maximus] 10/5/2018 09:56

algernon ... re: Confidentiality Clause. I contacted a wise friend ... "They have a number of them and have had in place most of the time." So no big deal.

[hugus maximus] 09/5/2018 23:21

Thanks Freedosh ... interesting then that you can roll over for the same money.

Curious algernon ... so what sort of info? Assume it's not possible to hold back something like a piece of 48 wk data? More likely a "pricing arrangement" type scenario? How is this facility usually used? This is a new one on me.

[algernon2] 09/5/2018 19:54

There appears to be a "Confidential Treatment Order" on the Nasdaq site as some form of RNS type notice.Anyone any idea re this?
---------------------
"Example of a Confidential Treatment Order
For example, a company may apply for a confidential treatment order by completing a confidential treatment request to keep information regarding a pricing arrangement made with a potential acquisition target secret. This request could be made on the basis that the company's competitors may use this information to go after the target with a more competitive price. Other common items kept confidential include milestone payments and other technical specifications."